Clinical trial · Interventional
Promoting INformed Approaches in Precision Oncology and ImmuNoTherapy
Reducing Racial Disparities in Cancer Care With PINPOINT (Promoting INformed Approaches in Precision Oncology and ImmuNoTherapy)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the research is to: develop an educational website to empower Black and African American cancer patients to make informed decisions about personalized cancer treatment and clinical trials. The sample size for the qualitative interviews was (n=48) when saturation was achieved. With a goal of (n=33) for the pilot trial, the overall target sample size for the study is (n=81).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Clinical Trials | — | UNRESOLVED | — |
| Immunotherapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PINPOINT Digital Educational Tool | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- PINPOINT Digital Educational Tool
- description
- Newly diagnosed Black cancer patients will be asked to access and engage with the educational website/intervention prototype before their clinic visit or in the clinic immediately before their appointment with their treating oncologist.
- interventionNames
- Behavioral: PINPOINT Digital Educational Tool
Primary outcomes (2)
- measure
- Acceptability of Intervention
- timeFrame
- Immediately following completion of the PINPOINT intervention during the pilot testing session (same day; intervention and exit survey completed within approximately 30-40 minutes total).
- description
- Measured using the 4-item Acceptability of Intervention Measure (AIM). Scores range from 1 to 5, with higher scores indicating greater acceptability. Cronbach's α = .85.
- measure
- Appropriateness of Intervention
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria Patient Key Informant: * Age 18 and older * Self-identify as Black/African American * Diagnosed with solid tumor * Able to read and speak English fluently * Able to provide informed consent * Able to complete 1 survey and an in-depth interview Relative Key Informant: * Age 18 and older * Spouse, blood relative, or caregiver of a cancer patient who identifies as Black/African American * Able to read and speak English fluently * Able to provide informed consent * Able to complete 1 survey and an in-depth interview Provider Key Informant: * Age 18 and older * Physician, nurse, social worker, patient navigator, or financial counselor * Work in oncology setting * Able to read and speak English fluently * Able to provide informed consent * Able to complete 1 survey and an in-depth interview Pilot Tester: * Age 18 and older * Self-identify as Black/African American * Able to read and speak English fluently * Able to provide informed consent * Newly diagnosed with solid tumor cancer (Stage I-IV) * Have not yet consulted with an oncologist regarding treatment * Able to complete 2 surveys and an in-depth interview Exclusion Criteria Key informants will be excluded from the study if they do not meet the inclusion criteria. Pilot testers will be excluded from the study if they previously participated as key informants and do not meet inclusion criteria.
References
Publications (0)
Data not yet available